<p>Supplemental Table 2 Literature verification of the gene sets obtained from the cent-stat method in AD</p><p>GO term GO term</p><p>ACTIN BINDING[1] NEGATIVE REGULATION OF PROGRAMMED</p><p>CELL DEATH[2] ACTIN CYTOSKELETON ORGANIZATION AND NEGATIVE REGULATION OF RNA METABOLIC</p><p>BIOGENESIS[3] PROCESS ACTIN FILAMENT BASED PROCESS NEGATIVE REGULATION OF</p><p>TRANSCRIPTION[4] ACTIN FILAMENT BINDING[1] NEGATIVE REGULATION OF TRANSCRIPTION</p><p>DNA DEPENDENT ACTIN FILAMENT BUNDLE FORMATION NERVOUS SYSTEM DEVELOPMENT[5]</p><p>ACTIN FILAMENT ORGANIZATION[6] NEUROPEPTIDE HORMONE ACTIVITY[4]</p><p>ACTIVATION OF NF KAPPAB TRANSCRIPTION NUCLEAR CHROMOSOME PART</p><p>FACTOR[7] AEROBIC RESPIRATION[8] NUCLEAR IMPORT[9] ANTI APOPTOSIS[10] NUCLEAR LUMEN APOPTOSIS GO NUCLEAR TRANSPORT[11] CELLULAR LOCALIZATION[12] NUCLEOBASE NUCLEOSIDE NUCLEOTIDE</p><p>KINASE ACTIVITY[13] CELLULAR RESPIRATION[14, 15] NUCLEOCYTOPLASMIC TRANSPORT[16]</p><p>CENTRAL NERVOUS SYSTEM NUCLEOSIDE TRIPHOSPHATASE</p><p>DEVELOPMENT[17] ACTIVITY[18] CHROMATIN MODIFICATION[19] ORGANELLE ENVELOPE[20] CHROMOSOME ORGANIZATION AND ORGANELLE INNER MEMBRANE[4]</p><p>BIOGENESIS[21] CLATHRIN COATED VESICLE[22] ORGANELLE LUMEN COATED VESICLE[23] ORGANELLE MEMBRANE[24]</p><p>COFACTOR CATABOLIC PROCESS[25] ORGANELLE ORGANIZATION AND</p><p>BIOGENESIS COVALENT CHROMATIN MODIFICATION PEPTIDE METABOLIC PROCESS CYTOPLASMIC MEMBRANE BOUND VESICLE PHOSPHOTRANSFERASE ACTIVITY</p><p>PHOSPHATE GROUP AS ACCEPTOR CYTOPLASMIC VESICLE[26] POSITIVE REGULATION OF BINDING</p><p>CYTOSKELETAL PROTEIN BINDING POSITIVE REGULATION OF DNA BINDING</p><p>CYTOSKELETON[27] POSITIVE REGULATION OF I KAPPAB KINASE</p><p>NF KAPPAB CASCADE CYTOSKELETON ORGANIZATION AND POSITIVE REGULATION OF SIGNAL</p><p>BIOGENESIS[28] TRANSDUCTION ENERGY DERIVATION BY OXIDATION OF POSITIVE REGULATION OF TRANSCRIPTION</p><p>ORGANIC COMPOUNDS[29, 30] FACTOR ACTIVITY ENVELOPE[31] POST TRANSLATIONAL PROTEIN</p><p>MODIFICATION[32] ESTABLISHMENT AND OR MAINTENANCE OF PROGRAMMED CELL DEATH[33]</p><p>CHROMATIN ARCHITECTURE ESTABLISHMENT OF CELLULAR PROTEIN IMPORT</p><p>LOCALIZATION[34] ESTABLISHMENT OF PROTEIN PROTEIN KINASE CASCADE[36]</p><p>LOCALIZATION[35] GTP BINDING[37] PROTEIN LOCALIZATION[35] GTPASE ACTIVITY[38] PROTEIN SERINE THREONINE KINASE</p><p>ACTIVITY[39] HISTONE MODIFICATION[40] PROTEIN TARGETING HYDROLASE ACTIVITY ACTING ON ACID PROTON TRANSPORTING TWO SECTOR</p><p>ANHYDRIDES ATPASE COMPLEX[41] I KAPPAB KINASE NF KAPPAB CASCADE[42] PYROPHOSPHATASE ACTIVITY[43] IDENTICAL PROTEIN BINDING[44] REGULATION OF APOPTOSIS[45]</p><p>INTRACELLULAR TRANSPORT[46] REGULATION OF BINDING[24] KINASE ACTIVITY[47] REGULATION OF DEVELOPMENTAL PROCESS</p><p>MACROMOLECULE LOCALIZATION REGULATIO N OF DNA BINDING[48] MAP KINASE KINASE KINASE ACTIVITY[49] REGULATION OF ENDOTHELIAL CELL</p><p>PROLIFERATION MEMBRANE BOUND VESICLE REGULATION OF I KAPPAB KINASE NF KAPPAB CASCADE</p><p>MEMBRANE ENCLOSED LUMEN REGULATION OF MOLECULAR</p><p>FUNCTION[50] MEMBRANE ORGANIZATION AND REGULATION OF PROGRAMMED CELL</p><p>BIOGENESIS[51] DEATH MITOCHONDRIAL ENVELOPE REGULATION OF RNA METABOLIC PROCESS</p><p>MITOCHONDRIAL INNER MEMBRANE[52] REGULATION OF TRANSCRIPTION DNA</p><p>DEPENDENT MITOCHONDRIAL MEMBRANE[53] REGULATION OF TRANSCRIPTION FACTOR</p><p>ACTIVITY[54] MITOCHONDRIAL MEMBRANE REGULATION OF TRANSCRIPTION FROM</p><p>ORGANIZATION AND BIOGENESIS RNA POLYMERASE II PROMOTER</p><p>MITOCHONDRIAL MEMBRANE PART[53] RIBONUCLEOPROTEIN COMPLEX[55]</p><p>MITOCHONDRIAL OUTER MEMBRANE[56] RNA PROCESSING[57] MITOCHONDRIAL PART[58] SMALL CONJUGATING PROTEIN BINDING</p><p>MITOCHONDRIAL TRANSPORT[59] SYNAPTIC VESICLE[60] MITOCHONDRION[61] TRANSCRIPTION FACTOR BINDING</p><p>MITOCHONDRION ORGANIZATION AND TRANSCRIPTION FROM RNA POLYMERASE II</p><p>BIOGENESIS PROMOTER NEGATIVE REGULATION OF APOPTOSIS TRANSCRIPTION REPRESSOR ACTIVITY[62]</p><p>NEGATIVE REGULATION OF CELLULAR TRANSFERASE ACTIVITY TRANSFERRING</p><p>COMPONENT ORGANIZATION AND PHOSPHORUS CONTAINING GROUPS</p><p>BIOGENESIS NEGATIVE REGULATION OF CELLULAR TRANSPORT VESICLE[63]</p><p>METABOLIC PROCESS NEGATIVE REGULATION OF DEVELOPMENTAL TRICARBOXYLIC ACID CYCLE INTERMEDIATE</p><p>PROCESS METABOLIC PROCESS NEGATIVE REGULATION OF METABOLIC TRNA PROCESSING</p><p>PROCESS NEGATIVE REGULATION OF NUCLEOBASE UBIQUITIN BINDING[64, 65]</p><p>NUCLEOSIDE NUCLEOTIDE AND NUCLEIC ACID</p><p>METABOLIC PROCESS</p><p>Reference: 1. Harigaya Y, Shoji M, Shirao T, Hirai S: Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J Neurosci Res 1996, 43:87-92. 2. Stadelmann C, Deckwerth TL, Srinivasan A, Bancher C, Bruck W, Jellinger K, Lassmann H: Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol 1999, 155:1459-1466. 3. Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB: Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol 2007, 9:139-148. 4. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ: Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down- regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002, 70:462-473. 5. Martin LJ: Neuronal cell death in nervous system development, disease, and injury (Review). Int J Mol Med 2001, 7:455-478. 6. Heredia L, Helguera P, de Olmos S, Kedikian G, Sola Vigo F, LaFerla F, Staufenbiel M, de Olmos J, Busciglio J, Caceres A, Lorenzo A: Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. J Neurosci 2006, 26:6533-6542. 7. Terai K, Matsuo A, McGeer PL: Enhancement of immunoreactivity for NF-kappa B in the hippocampal formation and cerebral cortex of Alzheimer's disease. Brain Res 1996, 735:159-168. 8. Datta K, Sinha S, Chattopadhyay P: Reactive oxygen species in health and disease. Natl Med J India 2000, 13:304-310. 9. Engidawork E, Gulesserian T, Seidl R, Cairns N, Lubec G: Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci Lett 2001, 303:79-82. 10. Paradis E, Douillard H, Koutroumanis M, Goodyer C, LeBlanc A: Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J Neurosci 1996, 16:7533-7539. 11. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C: Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1997, 94:2642-2647. 12. De Strooper B, Beullens M, Contreras B, Levesque L, Craessaerts K, Cordell B, Moechars D, Bollen M, Fraser P, George-Hyslop PS, Van Leuven F: Phosphorylation, subcellular localization, and membrane orientation of the Alzheimer's disease-associated presenilins. J Biol Chem 1997, 272:3590-3598. 13. Hoerndli FJ, Pelech S, Papassotiropoulos A, Gotz J: Abeta treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry. Eur J Neurosci 2007, 26:60-72. 14. Barnham KJ, McKinstry WJ, Multhaup G, Galatis D, Morton CJ, Curtain CC, Williamson NA, White AR, Hinds MG, Norton RS, et al: Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 2003, 278:17401-17407. 15. Kong GK, Adams JJ, Cappai R, Parker MW: Structure of Alzheimer's disease amyloid precursor protein copper-binding domain at atomic resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun 2007, 63:819-824. 16. Sheffield LG, Miskiewicz HB, Tannenbaum LB, Mirra SS: Nuclear pore complex proteins in Alzheimer disease. J Neuropathol Exp Neurol 2006, 65:45-54. 17. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson- Wood K, et al: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6:916-919. 18. Furuta A, Iida T, Nakabeppu Y, Iwaki T: Expression of hMTH1 in the hippocampi of control and Alzheimer's disease. Neuroreport 2001, 12:2895-2899. 19. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH: Recovery of learning and memory is associated with chromatin remodelling. Nature 2007, 447:178-182. 20. Fraser PE, Yang DS, Yu G, Levesque L, Nishimura M, Arawaka S, Serpell LC, Rogaeva E, St George-Hyslop P: Presenilin structure, function and role in Alzheimer disease. Biochim Biophys Acta 2000, 1502:1-15. 21. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, et al.: The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987, 235:885-890. 22. Nordstedt C, Caporaso GL, Thyberg J, Gandy SE, Greengard P: Identification of the Alzheimer beta/A4 amyloid precursor protein in clathrin-coated vesicles purified from PC12 cells. J Biol Chem 1993, 268:608-612. 23. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D: Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J Neurosci 1996, 16:5795-5811. 24. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A, Cuervo AM: Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol 2005, 64:113-122. 25. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC: Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 2000, 6:143-150. 26. Lotharius J, Brundin P: Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha- synuclein. Nat Rev Neurosci 2002, 3:932-942. 27. Wood JG, Mirra SS, Pollock NJ, Binder LI: Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc Natl Acad Sci U S A 1986, 83:4040-4043. 28. David DC, Ittner LM, Gehrig P, Nergenau D, Shepherd C, Halliday G, Gotz J: Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics 2006, 6:6566-6577. 29. Lipton SA, Gu Z, Nakamura T: Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders. Int Rev Neurobiol 2007, 82:1-27. 30. Tabner BJ, Turnbull S, El-Agnaf O, Allsop D: Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. Curr Top Med Chem 2001, 1:507-517. 31. Zimmermann K, Herget T, Salbaum JM, Schubert W, Hilbich C, Cramer M, Masters CL, Multhaup G, Kang J, Lemaire HG, et al.: Localization of the putative precursor of Alzheimer's disease-specific amyloid at nuclear envelopes of adult human muscle. EMBO J 1988, 7:367- 372. 32. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K: Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 2005, 112:813-838. 33. Rao RV, Ellerby HM, Bredesen DE: Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ 2004, 11:372-380. 34. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL: The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 1992, 9:129-137. 35. Kowall NW, Kosik KS: Axonal disruption and aberrant localization of tau protein characterize the neuropil pathology of Alzheimer's disease. Ann Neurol 1987, 22:639-643. 36. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD: Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001, 21:4125-4133. 37. Nishimoto I, Okamoto T, Matsuura Y, Takahashi S, Murayama Y, Ogata E: Alzheimer amyloid protein precursor complexes with brain GTP-binding protein G(o). Nature 1993, 362:75-79. 38. Cutler R, Joseph JA, Yamagami K, Villalobos-Molina R, Roth GS: Area specific alterations in muscarinic stimulated low Km GTPase activity in aging and Alzheimer's disease: implications for altered signal transduction. Brain Res 1994, 664:54-60. 39. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH: Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992, 147:58-62. 40. Berger SL: Histone modifications in transcriptional regulation. Curr Opin Genet Dev 2002, 12:142-148. 41. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA: Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 2005, 1044:206-215. 42. Yamamoto Y, Gaynor RB: IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 2004, 29:72-79. 43. Mastrogiacomo F, Bergeron C, Kish SJ: Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem 1993, 61:2007-2014. 44. He XY, Schulz H, Yang SY: A human brain L-3-hydroxyacyl-coenzyme A dehydrogenase is identical to an amyloid beta-peptide-binding protein involved in Alzheimer's disease. J Biol Chem 1998, 273:10741-10746. 45. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J: Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 2004, 13:1225-1240. 46. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, Mandelkow E: Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 1998, 143:777-794. 47. Lee KY, Clark AW, Rosales JL, Chapman K, Fung T, Johnston RN: Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci Res 1999, 34:21-29. 48. Lukiw WJ, Bazan NG: Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 1998, 53:583-592. 49. Goedert M, Cohen ES, Jakes R, Cohen P: p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected]. FEBS Lett 1992, 312:95-99. 50. Brinton RD: Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem 2001, 8:121-133. 51. Kaminska J, Hoffman-Sommer M, Plachta M: [The p24 family proteins--regulators of vesicular trafficking]. Postepy Biochem, 56:75-82. 52. Wallace DC: Mitochondrial diseases in man and mouse. Science 1999, 283:1482-1488. 53. Cassarino DS, Swerdlow RH, Parks JK, Parker WD, Jr., Bennett JP, Jr.: Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 1998, 248:168-173. 54. Murrell J, Farlow M, Ghetti B, Benson MD: A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991, 254:97-99. 55. Mehler MF, Mattick JS: Non-coding RNAs in the nervous system. J Physiol 2006, 575:333- 341. 56. Lin MT, Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443:787-795. 57. Lukiw WJ: Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007, 18:297-300. 58. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, et al: Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001, 21:3017-3023. 59. Parker WD, Jr., Parks J, Filley CM, Kleinschmidt-DeMasters BK: Electron transport chain defects in Alzheimer's disease brain. Neurology 1994, 44:1090-1096. 60. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, Coleman PD: Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis 2003, 12:97-109. 61. Mecocci P, MacGarvey U, Beal MF: Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994, 36:747-751. 62. Shi J, Zhang S, Tang M, Ma C, Zhao J, Li T, Liu X, Sun Y, Guo Y, Han H, et al: Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons. J Gerontol A Biol Sci Med Sci 2005, 60:301-306. 63. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LS: Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature 2001, 414:643-648. 64. Kuusisto E, Suuronen T, Salminen A: Ubiquitin-binding protein p62 expression is induced during apoptosis and proteasomal inhibition in neuronal cells. Biochem Biophys Res Commun 2001, 280:223-228. 65. Kuusisto E, Salminen A, Alafuzoff I: Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001, 12:2085- 2090.</p>